fda banned semaglutide bans compounded and tirzepatide ban on The End of Compounded Semaglutide: Why the FDA's Decision Matters for is fda stopping compounded tirzepatide – FDA moves to remove GLP-1

These observations support growing evidence that semaglutide's effects extend beyond weight management and glucose control, while also highlighting that weight loss alone may not be an adequate surrogate for predicting cardiovascular benefit

The clinical trials showed that at least four weeks at each dose level is necessary for the body to adapt

For patients with type 2 diabetes, HbA1c levels are closely tracked to adjust any concurrent diabetes medications (like insulin or sulfonylureas) to prevent hypoglycemia

For this reason, providers often encourage patients to track: rather than focusing only on the number on the scale

However, Hula advises giving your body some time to adjust after weight loss before considering treatment